Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Expected to Reach $3,528.8 Million, by 2026
Acute lymphocytic/lymphoblastic leukemia therapeutics market size was valued at $2,334.5 million in 2018, and is projected to reach $3,528.8 million by 2026, growing at a CAGR of 5.3% from 2019 to 2026. Acute lymphocytic/lymphoblastic leukemia (ALL) is one of the types of leukemia, which is highly prevalent in pediatrics and also observed in adults. There are various therapy options for ALL treatment including chemotherapy, targeted therapy, and immunotherapy. ALL treatments witness high success rates in pediatric population, however, in adult population have low success rates. Chemotherapy is a first line treatment option in majority of ALL cases. Rise in incidences of acute lymphoblastic leukemia and the number of bone marrow biopsies across the world are the major factors that boost the growth of the acute lymphocytic/lymphoblastic leukemia therapeutics market. However, the stringent regulatory approvals for the therapeutics and the adverse side effect of the drugs used in th...